# MariTide Side Effects: GI Tolerability and Monthly Titration
> Note: PeptIQ is not a medical provider. MariTide is investigational. Not a complete safety label.
MariTide sits in the incretin-adjacent obesity class, so beginners should expect gastrointestinal adverse events — nausea, vomiting, diarrhea, constipation, early fullness — especially when starting high or skipping escalation.
What Phase 2 Communications Emphasized
- GI events were common
- They were less frequent with dose escalation and lower starting doses
- No unexpected safety signals highlighted in top-line sponsor/NEJM framing
- Efficacy remained meaningful across studied monthly arms
That combination is why titration design is part of the MariTide story, not an afterthought.
Monthly vs Weekly Side-Effect Shape
| Weekly GLP-1-class | Monthly MariTide-style | |
|---|---|---|
| Exposure rhythm | Smaller weekly steps | Larger pulses every 4 weeks |
| Symptom logging | Dose-day + 48–72h | Often a longer early-week window after the monthly shot |
| Missed dose psychology | Easy to "skip one week" | Missing a month is a bigger adherence gap |
Tracking Checklist (0–10 scores)
For 4–5 days after each monthly injection:
- Nausea
- Vomiting / dry heaving
- Early fullness
- Constipation / diarrhea
- Energy
- Protein target hit (yes/no)
- Training completed (yes/no)
Also log hydration and whether the dose was an escalation step.
